Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.

Int J Infect Dis · 2022 · PMC8531242 · PMID 34688944

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

In this study, there was a decreasing trend in anti-spike antibodies, anti-RBD antibodies and nAb titres with increasing age, although large variability was observed among individual titres with wide, overlapping CIs between age groups.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.